Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enasidenib in IDH2-mutated Malignant Sinonasal and Skull Base Tumors
NCT06176989Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enasidenib in sinonasal undifferentiated carcinoma (SNUC), olfactory neuroblastoma (ONB), large cell neuroendocrine carcinoma (LCNEC) and 2 more, sponsored by National Cancer Institute. Primary endpoint: Progression Free Survival up to 5 years. Started Mar 2024; status: recruiting.
02
Drugs
enasidenib
03
Conditions
sinonasal undifferentiated carcinoma (SNUC)olfactory neuroblastoma (ONB)large cell neuroendocrine carcinoma (LCNEC)sinonasal adenocarcinomachondrosarcoma
Beyond the preview
Go deeper on NCT06176989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06176989.